Jpmorgan Chase & CO Annovis Bio, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 8,800 shares of ANVS stock, worth $24,376. This represents 0.0% of its overall portfolio holdings.
Number of Shares
8,800
Previous 3,800
131.58%
Holding current value
$24,376
Previous $19,000
31.58%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ANVS
# of Institutions
52Shares Held
2.18MCall Options Held
88.1KPut Options Held
188K-
Vanguard Group Inc Valley Forge, PA697KShares$1.93 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA183KShares$507,7040.0% of portfolio
-
Two Sigma Investments, LP New York, NY166KShares$460,4260.0% of portfolio
-
Ubs Group Ag161KShares$445,6260.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA128KShares$353,7420.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $22.6M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...